emd 53998 has been researched along with n-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide in 1 studies
Studies (emd 53998) | Trials (emd 53998) | Recent Studies (post-2010) (emd 53998) | Studies (n-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide) | Trials (n-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide) | Recent Studies (post-2010) (n-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide) |
---|---|---|---|---|---|
112 | 0 | 9 | 24 | 5 | 5 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Borbély, A; Edes, I; Papp, Z; Stienen, GJ; Van Der Velden, J | 1 |
1 other study(ies) available for emd 53998 and n-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide
Article | Year |
---|---|
Effects of Ca2+ -sensitizers in permeabilized cardiac myocytes from donor and end-stage failing human hearts.
Topics: Acetamides; Adult; Aged; Calcium; Cell Membrane Permeability; Female; Heart Failure; Humans; In Vitro Techniques; Male; Middle Aged; Myocardium; Myocytes, Cardiac; Pyridazines; Quinolines; Thiadiazines; Tissue Donors | 2004 |